Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tirzepatide to Reduce Recurrence and Burden After Catheter Ablation of Atrial Fibrillation: A Prospective Randomized Trial

NCT07382024 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT07382024
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07382024 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tirzepatide to Reduce Recurrence and Burden After Catheter Ablation of Atrial Fibrillation: A Prospective Randomized Trial
Lead sponsor
National Taiwan University Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
June 16, 2026
Completion date
July 31, 2028
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation ablation, obesity & overweight, persistent atrial fibrillation